新辅助纳武利尤单抗联合化疗后按缓解分层的放化疗治疗HPV阴性头颈癌:DEPEND 2期非随机临床试验
DEPEND 2期非随机试验在单个学术中心纳入36例HPV阴性局部晚期IVa/b期头颈鳞癌患者,评估新辅助纳武利尤单抗联合卡铂和紫杉醇后按缓解分层放化疗的深度缓解率与耐受性。新辅助治疗后深度缓解率为53%(95%CI 35-70),2年无进展生存率和总生存率分别为66%(95%CI 34-76)和73%(95%CI 52-86)。
要点
- 新辅助纳武利尤单抗联合化疗深度缓解率达53%(95%CI 35-70),客观缓解率86%(95%CI 71-95)。
- 深度缓解者接受降级放化疗至66 Gy并省略选择性淋巴结区,2年PFS 66%、OS 73%。
- 降级放化疗组口腔黏膜炎74%、放射性皮炎68%、口干37%,低于标准放化疗组的94%、88%、63%。
核心结论
- 在新辅助纳武利尤单抗联合化疗后,53%的HPV阴性局部晚期IVa/b期头颈鳞癌患者达到深度缓解。
- 按缓解分层的降级放化疗使深度缓解者获得良好生存且急性毒性反应较低。
研究设计与样本
- 研究者发起的2期非随机临床试验,在单个学术中心开展。
- 纳入36例HPV阴性局部晚期IVa/b期头颈鳞癌患者,2019年至2022年入组,数据分析时间为2023年2月至2024年1月。
- 干预为新辅助纳武利尤单抗联合卡铂和紫杉醇,随后按缓解分层放化疗,辅助纳武利尤单抗9个周期。
主要发现
- 36例患者中28例(78%)为男性,中位(范围)年龄58.9(27-77)岁,中位(范围)随访20(13-40)个月。
- 新辅助治疗后深度缓解率为53%(95%CI 35-70),客观缓解率为86%(95%CI 71-95)。
- 19例接受降级放化疗,16例接受标准放化疗;2年无进展生存率为66%(95%CI 34-76),2年总生存率为73%(95%CI 52-86)。
- 降级放化疗组与标准放化疗组最常见的治疗中出现的不良事件分别为口腔黏膜炎14/19(74%) vs 15/16(94%)、放射性皮炎13/19(68%) vs 14/16(88%)、口干7/19(37%) vs 10/16(63%)。
关键数值与推荐
- 深度缓解定义为RECIST 1.1版评估缩小≥50%。
- 缩小≥50%者接受降级放化疗至66 Gy并省略选择性淋巴结区;缩小<50%者接受标准放化疗至70-75 Gy。
- 辅助纳武利尤单抗给药9个周期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neoadjuvant immunotherapy in human papillomavirus (HPV)-negative locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) appears promising, yet its role in nonsurgical treatment for head and neck cancer remains undefined. Neoadjuvant nivolumab plus chemotherapy followed by response-stratified de-escalated chemoradiation therapy (CRT) in HPV-negative LA stage IVa/b HNSCC may improve treatment efficacy while reducing treatment-related toxic effects. OBJECTIVE: To determine the deep response rate and tolerability of neoadjuvant nivolumab plus chemotherapy followed by response-stratified CRT in nonvirally mediated stage IVa/b HNSCC. DESIGN, SETTING, AND PARTICIPANTS: In this investigator-initiated phase 2 nonrandomized clinical trial conducted at a single academic center, patients with stage IVa/b (American Joint Committee on Cancer Tumor Classification, 8th edition) HPV-negative LA HNSCC were enrolled between 2019 and 2022. Data were analyzed from February 2023 to January 2024. INTERVENTIONS: The DEPEND trial evaluated neoadjuvant nivolumab plus carboplatin and paclitaxel, followed by response-stratified CRT. Patients with 50% or greater reduction per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 received de-escalated CRT to 66 Gy with elimination of elective nodal volumes; patients with less than 50% reduction received standard CRT to 70 to 75 Gy. Adjuvant nivolumab was administered for 9 cycles. MAIN OUTCOMES AND MEASURES: The primary end point was deep response rate (DRR; 50% or greater shrinkage per RECIST version 1.1) following neoadjuvant nivolumab plus chemotherapy. Secondary end points included progression-free survival (PFS), overall survival (OS), locoregional control, and distant control. Exploratory end points included acute toxic effects in patients who received response-adapted de-escalated CRT. RESULTS: Of 36 included patients, 28 (78%) were male, and the median (range) age was 58.9 (27-77) years. All patients started treatment and were available for analysis. The median (range) follow-up was 20 (13-40) months. The primary end point was met, with a DRR following neoadjuvant nivolumab/chemotherapy of 53% (95% CI, 35-70). The objective response rate was 86% (95% CI, 71-95). A total of 19 received de-escalated CRT and 16 received standard CRT. PFS and OS at 2 years were 66% (95% CI, 34-76) and 73% (95% CI, 52-86), respectively. The most common treatment-emergent adverse events for de-escalated and standard CRT were mucositis (14 of 19 [74%] and 15 of 16 [94%], respectively), radiation dermatitis (13 of 19 [68%] and 14 of 16 [88%], respectively), and dry mouth (7 of 19 [37%] and 10 of 16 [63%], respectively). CONCLUSIONS AND RELEVANCE: In this phase 2 nonrandomized clinical trial, neoadjuvant nivolumab/chemotherapy led to deep responses in 53% of patients with HPV-negative LA stage IVa/b HNSCC, and response-adapted de-escalated CRT led to favorable survival with lower acute toxic effects among deep responders. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03944915.
引用
- Rosenberg AJ, Juloori A, Jelinek MJ, et al. Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025. PMID: 40048190. doi:10.1001/jamaoncol.2025.0081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。